138 related articles for article (PubMed ID: 7624919)
21. Comparison of vancomycin pharmacokinetics in hospitalized elderly and young patients using a Bayesian forecaster.
Guay DR; Vance-Bryan K; Gilliland S; Rodvold K; Rotschafer J
J Clin Pharmacol; 1993 Oct; 33(10):918-22. PubMed ID: 8227461
[TBL] [Abstract][Full Text] [Related]
22. Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting.
Broeker A; Nardecchia M; Klinker KP; Derendorf H; Day RO; Marriott DJ; Carland JE; Stocker SL; Wicha SG
Clin Microbiol Infect; 2019 Oct; 25(10):1286.e1-1286.e7. PubMed ID: 30872102
[TBL] [Abstract][Full Text] [Related]
23. Vancomycin pharmacokinetics in middle-aged and elderly men.
Leonard AE; Boro MS
Am J Hosp Pharm; 1994 Mar; 51(6):798-800. PubMed ID: 8010319
[TBL] [Abstract][Full Text] [Related]
24. Bayesian Vancomycin Model Selection for Therapeutic Drug Monitoring in Neonates.
Alrahahleh D; Thoma Y; Van Daele R; Nguyen T; Halena S; Luig M; Stocker S; Kim HY; Alffenaar JW
Clin Pharmacokinet; 2024 Mar; 63(3):367-380. PubMed ID: 38416322
[TBL] [Abstract][Full Text] [Related]
25. Influences of renal function descriptors on population pharmacokinetic modeling of vancomycin in Chinese adult patients.
Ji XW; Ji SM; He XR; Zhu X; Chen R; Lu W
Acta Pharmacol Sin; 2018 Feb; 39(2):286-293. PubMed ID: 28836582
[TBL] [Abstract][Full Text] [Related]
26. Accuracy of predicting the vancomycin concentration in Japanese cancer patients by the Sawchuk-Zaske method or Bayesian method.
Nakashima T; Ohno T; Koido K; Hashimoto H; Terakado H
J Oncol Pharm Pract; 2020 Apr; 26(3):543-548. PubMed ID: 31142231
[TBL] [Abstract][Full Text] [Related]
27. [Pharmacokinetics of vancomycin in patients with severe acute pancreatitis and its influencing factors: analysis of 7 years data].
He J; Mao E; Jing F; Jiang H; Yang W; Chen E
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2017 Jun; 29(6):491-495. PubMed ID: 28625235
[TBL] [Abstract][Full Text] [Related]
28. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique.
Vance-Bryan K; Guay DR; Gilliland SS; Rodvold KA; Rotschafer JC
Antimicrob Agents Chemother; 1993 Mar; 37(3):436-40. PubMed ID: 8460912
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations.
Mehrotra N; Tang L; Phelps SJ; Meibohm B
Pharmacotherapy; 2012 May; 32(5):408-19. PubMed ID: 22488303
[TBL] [Abstract][Full Text] [Related]
30. Vancomycin pharmacokinetics and Bayesian estimation in pediatric patients.
Wrishko RE; Levine M; Khoo D; Abbott P; Hamilton D
Ther Drug Monit; 2000 Oct; 22(5):522-31. PubMed ID: 11034256
[TBL] [Abstract][Full Text] [Related]
31. [Bayesian forecasting of plasma vancomycin concentration using time-dependent pharmacokinetics].
Nakamura T; Wakaki N; Kimura Y; Goto N; Masada M
Yakugaku Zasshi; 1996 Nov; 116(11):876-83. PubMed ID: 8981831
[TBL] [Abstract][Full Text] [Related]
32. Dose regimen for vancomycin not needing serum peak levels?
Tan WH; Brown N; Kelsall AW; McClure RJ
Arch Dis Child Fetal Neonatal Ed; 2002 Nov; 87(3):F214-6. PubMed ID: 12390995
[TBL] [Abstract][Full Text] [Related]
33. Population pharmacokinetics and dose optimization of vancomycin in neonates.
Lee SM; Yang S; Kang S; Chang MJ
Sci Rep; 2021 Mar; 11(1):6168. PubMed ID: 33731764
[TBL] [Abstract][Full Text] [Related]
34. Population pharmacokinetics of vancomycin in Chinese infants
.
Sheng XY; Chen CY; Ma LY; Liu YO; Zhou Y; Cui YM
Int J Clin Pharmacol Ther; 2017 Jul; 55(7):558-566. PubMed ID: 28406088
[TBL] [Abstract][Full Text] [Related]
35. Prediction of serum vancomycin concentrations using one-, two- and three-compartment models with implemented population pharmacokinetic parameters and with the Bayesian method.
Wu G; Furlanut M
J Pharm Pharmacol; 1998 Aug; 50(8):851-6. PubMed ID: 9751448
[TBL] [Abstract][Full Text] [Related]
36. Influence of malignancy on the pharmacokinetics of vancomycin in infants and children.
Chang D
Pediatr Infect Dis J; 1995 Aug; 14(8):667-73. PubMed ID: 8532423
[TBL] [Abstract][Full Text] [Related]
37. Performance of Bayesian Area Under the Concentration-Time Curve-Based Pharmacokinetic Dosing Based on a One-Compartment Model and Trough-Only Monitoring for Vancomycin.
Salehpour N; Riley LD; Gonzales MJ; Kobic E; Nix DE
Antimicrob Agents Chemother; 2023 Jun; 67(6):e0017223. PubMed ID: 37133362
[TBL] [Abstract][Full Text] [Related]
38. Vancomycin population pharmacokinetics in neonates.
de Hoog M; Schoemaker RC; Mouton JW; van den Anker JN
Clin Pharmacol Ther; 2000 Apr; 67(4):360-7. PubMed ID: 10801244
[TBL] [Abstract][Full Text] [Related]
39. Decreased vancomycin clearance in patients with congestive heart failure.
Shimamoto Y; Fukuda T; Tominari S; Fukumoto K; Ueno K; Dong M; Tanaka K; Shirasaka T; Komori K
Eur J Clin Pharmacol; 2013 Mar; 69(3):449-57. PubMed ID: 22791272
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of Neonatal and Paediatric Vancomycin Pharmacokinetic Models and the Impact of Maturation and Serum Creatinine Covariates in a Large Multicentre Data Set.
Hughes JH; Tong DMH; Faldasz JD; Frymoyer A; Keizer RJ
Clin Pharmacokinet; 2023 Jan; 62(1):67-76. PubMed ID: 36404388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
